Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Yarrow Bioscience, Inc.
13G
YARW · 92941V407
|
10.6% |
10/7/2026
Event 9/10/2026
|
|||
| Bellevue Group AG | 10.6% | ||||
| Bellevue Asset Management AG | 10.6% | ||||
|
Jade Biosciences, Inc.
13G/A
Amendment 1
JBIO · 008064206
|
5.0% |
8/14/2026
Event 6/30/2026
|
|||
| Bellevue Group AG | 5.0% | ||||
| Bellevue Asset Management AG | 5.0% | ||||
|
Viridian Therapeutics, Inc.
13G
VRDN · 92790C104
|
6.6% |
5/15/2026
Event 3/31/2026
|
|||
| Bellevue Group AG | 6.6% | ||||
| Bellevue Asset Management AG | 6.6% | ||||
|
Celldex Therapeutics, Inc.
13G/A
Amendment 1
CLDX · 15117B202
|
1.5% |
5/15/2026
Event 3/31/2026
|
|||
| Bellevue Group AG | 1.5% | ||||
| Bellevue Asset Management AG | 1.5% | ||||
|
Jade Biosciences, Inc.
13G
JBIO · 008064206
|
6.8% |
2/17/2026
Event 12/16/2025
|
|||
| Bellevue Group AG | 6.8% | ||||
| Bellevue Asset Management AG | 6.8% | ||||
|
MacroGenics, Inc.
13G/A
Amendment 1
MGNX · 556099109
|
0% |
1/6/2026
Event 12/5/2025
|
|||
| Bellevue Group AG | 0% | ||||
| Bellevue Asset Management AG | 0% | ||||
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 1
AGIO · 00847X104
|
0% |
12/5/2025
Event 11/19/2025
|
|||
| Bellevue Group AG | 0% | ||||
| Bellevue Asset Management AG | 0% | ||||
|
Immunocore Holdings plc
13G
IMCR · 45258D105
|
5.6% |
11/14/2025
Event 8/20/2025
|
|||
| Bellevue Group AG | 5.6% | ||||
| Bellevue Asset Management AG | 5.6% | ||||
|
Celldex Therapeutics, Inc.
13G
CLDX · 15117B202
|
5.4% |
11/14/2025
Event 8/18/2025
|
|||
| Bellevue Group AG | 5.4% | ||||
| Bellevue Asset Management AG | 5.4% | ||||
|
Agios Pharmaceuticals, Inc.
13G
AGIO · 00847X104
|
6.1% |
7/7/2025
Event 6/1/2025
|
|||
| Bellevue Group AG | 6.1% | ||||
| Bellevue Asset Management AG | 6.1% | ||||
|
MacroGenics, Inc.
13G
MGNX · 556099109
|
15.7% |
7/7/2025
Event 6/1/2025
|
|||
| Bellevue Group AG | 15.7% | ||||
| Bellevue Asset Management AG | 15.7% | ||||